Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT

Journal of Hepatology

Volumn 30, Issue 2, 1999, Pages 192-198

  Brouwer, Johannes T ^a   Hansen, Bettina E ^a   Niesters, Hubert G M ^a   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alanine aminotransferase; HCV RNA; Hepatitis C; Interferon alfa 2b; Monitoring of therapy; On treatment response; Predictive value; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG MIXTURE; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032940812     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80061-0     Document Type: Article

References (22)

1. Anonymous. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology. 26:1997;2S-10S.
2. Dhumeaux D, Doffoel M, Galmiche JP. A French consensus conference on hepatitis C: screening and treatment. J Hepatol. 27:1997;941-944.
3. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology. 22:1995;700-706.
4. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol. 23:1995;487-496.
5. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med. 332:1995;1457-1462.
6. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 26:1997;122S-127S.
7. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology. 26:1997;1640-1645.
8. Kleter GE, Brouwer JT, Heijtink RA, Schalm SW, Quint WG. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother. 37:1993;595-597.
9. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol. 28:1998;951-959.
10. Brouwer JT, Nevens F, Michielsen P, Hautekeete ML, Chamuleau RAFM, Adler M, et al. What options are left when hepatitis C does not respond to interferon? Placebo controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon. [abstract] J Hepatol. 21:((suppl 1)):1994;S17.
11. Kleter GE, van Doorn LJ, Brouwer JT, Schalm SW, Heijtink RA, Quint WG. Sequence analysis of the 5′ untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands. J Clin Microbiol. 32:1994;306-310.
12. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 26:1997;71S-77S.
13. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 44:1988;837-845.
14. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
15. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centres. J Hepatol. 26:1997;961-966.
16. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O Randomised. double-blind, placebo-controlled trial of interferon alpha- 2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 351:1998;83-87.
17. Gavier B, Martincz-Gonzalez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology. 113:1997;1647-1653.
18. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology. 27:1998;1149-1156.
19. Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatology. 26:1997;1-4.
20. Damen M, Cuypers HT, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, et al. International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods. 58:1996;175-185.
21. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci. 38:1993;612-618.
22. Bekkering FC, Brouwer JT, Leroux-Roels G, Vlierberghe H van, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol. 28:1998;960-964.